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Abstract 
Background: The role of reoperation for recurrent GBM remains unclear. 
Prospective studies are lacking. Here, we studied the association of clinical outcome 
with extent of resection upon surgery for recurrent GBM in the patient cohort of 
DIRECTOR, a prospective randomized multicenter trial comparing two dose-
intensified temozolomide (TMZ) regimens at recurrence of GBM. 
Methods: We analyzed prospectively collected clinical and imaging data from the 
DIRECTOR cohort (N=105). Volumetric analysis was performed on gadolinium (CE)-
enhanced as well as FLAIR/T2 MRI and correlated with progression-free survival 
after initial progression (PFS2) and post recurrence-survival (PRS). Quality of life 
(QoL) was monitored by EORTC QLQ-C30 and QLQ-BN20 in 8-weekly intervals.  
Results: Seventy-one patients received surgery at first recurrence. Prognostic 
factors, including age, MGMT promoter methylation and Karnofsky performance 
score were balanced between patients with and without reoperation. Outcome in 
patients with versus without surgery at recurrence was similar for PFS2 (2.0 months 
versus 1.9 months, p=0.360) and PRS (11.4 months versus 9.8 months, p=0.633). 
Among re-operated patients, post-surgery imaging was available in 59 cases. In 
these patients, complete resection of CE-enhancing tumor (N=40) versus residual 
detection of CE enhancement (N=19) was associated with improved PRS (12.9 
months [95% CI 11.5-18.2] versus 6.5 months [95% CI 3.6-9.9], p<0.001) and better 
QoL. Incomplete tumor resection was associated with inferior PRS compared to 
patients who did not undergo surgery (6.5 versus 9.8 months, p=0.052). QoL was 
similar in these two groups. 
Conclusions: Surgery at first recurrence of GBM improves outcome if complete 
resection of CE-enhancing tumor is achieved. 
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Introduction 
 
Standard of care in GBM consists of gross total resection whenever feasible followed 
by involved field irradiation (RT) with concomitant temozolomide (TMZ) 
chemotherapy and subsequent 6 cycles of maintenance TMZ1. Since introduction of 
this standard2, overall survival has increased to approximately 16 months in clinical 
trials, with superior outcome of 25-30 months in patients with MGMT promoter 
methylation3-5. Microsurgical tumor resection as initial treatment contributes to 
prolonged overall survival, if complete resection of contrast enhancing tumor (CRET) 
is achieved6-9. While CRET is considered to be the gold-standard whenever safely 
feasible at the time of initial diagnosis, its value at recurrence is still subject to 
debate10. The skepticism about the value of surgical resection in recurrent GBM may 
be due to the poor prognosis of patients with recurrent GBM11, a rather high 
incidence of surgical morbidity following reoperation12 and the general debate on the 
value of microsurgical reduction of tumor burden in malignant glioma. The recently 
published prospective randomized multicenter DIRECTOR trial evaluated the efficacy 
and tolerability of two different regimens of temozolomide (TMZ) at first progression 
after adjuvant chemoradiotherapy (TMZ/RTTMZ)13. Major inclusion criteria were 
progressive or recurrent GBM as documented with MRI no earlier than 180 days after 
first surgery and no earlier than 90 days after end of RT. Furthermore, information 
about MGMT methylation status and completion of concomitant RT/TMZ plus at least 
2 cycles of maintenance TMZ were required. Patients with and without reoperation 
were included. A Karnofsky performance score (KPS) of > 50 was mandatory for 
inclusion. All patients received either regimen of a dose intensified TMZ re-challenge 
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– both arms showed similar outcome.  Thus, this data set provides a well-annotated 
patient cohort to analyze the association of extent of resection (EOR) on the basis of 
MRI volumetry with outcome in the framework of a well-controlled post-recurrence 
treatment setting. 
 
Methods 
 
Study design 
GBM patients enrolled in the DIRECTOR trial were analyzed for associations of 
surgery and EOR at first progression with outcome. Indication for surgery was 
commonly based on recommendations from multidisciplinary tumor boards. Outcome 
measures were time to next progression (PFS2, as opposed to the time of diagnosis 
to first progression, PFS1) and post recurrence survival (PRS). PFS2 was defined as 
the duration from the date of first study drug administration until further progression. 
PRS was defined as the duration from the date of the first study drug administration 
to the date of tumor related death. 
Disease status was monitored by MRI in 8-weekly intervals and assessed using 
Macdonald criteria14. At the time of data analysis (April 17, 2015), tumor progression 
had been documented in 99 patients, and death in 95 of all 105 patients, all tumor-
related. Three patients were lost to follow-up before tumor progression. The 
DIRECTOR study was approved by the local ethical committees; all patients gave 
written informed consent prior to inclusion.  
 
Neuroimaging studies 
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Imaging data available from the original DIRECTOR trial was retrospectively 
analyzed for the present study while all remaining data was based on prospective 
analyses. Post-surgical MRI was performed within 72 hours following surgery.  
Volumetric analyses of pre- and postsurgical MR images were performed by an 
experienced investigator (B.S.) blinded to patients’ outcome. Manual segmentation of 
pre- and postsurgical contrast-enhanced (CE-) T1 and T2/FLAIR images was 
performed using the pencil-drawing tool of the Osirix Software, Version 3.6.1 
(Internetfreeware). Volume calculation of (CE-) T1 and T2/FLAIR tumor portion was 
performed by multiplying the sum of tumor areas outlined on each transverse slice by 
the corresponding slice thickness15. In case of blood remnants along the borders of 
the resection cavity, pre-contrast T1 volume was subtracted from the (CE-) T1 
volume. 
Concerning the (CE-) T1 image sequences, we obtained both: volumes with necrotic 
or cystic areas including enhancing parts as well as volumes with solid enhancing 
parts only. Resection cavities resulting from surgery were not included, neither in the 
(CE-) T1 nor in the T2/FLAIR volume calculation. 
In the surgery cohort, which did not include biopsies, CRET was defined as absence 
of any contrast enhancing tumor volume on (CE-) T1 imaging, while incomplete 
resection refers to patients with remnant CE-enhancing tumor after surgical 
procedure. 
In addition, an analysis considering the functional relevance (motor/supplementary 
motor cortex, primary somatosensitive area, Broca and Wernicke area) of the 
affected brain area was performed: tumor location was classified as ‘’eloquent’’ 
versus ‘’non-eloquent’’ accordingly16.  
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Quality of life 
Quality of life (QoL) was monitored by EORTC quality of life questionnaire (QLQ)-
C30 and QLQ-BN20 in 8-weekly intervals13. The QLQ-C30 incorporates five 
functional scales: general physical symptoms, physical functioning, psychological 
distress, social functioning, and fatigue/malaise. The BN20 is a module developed in 
particular for patients with brain cancer and comprises four domain scores (future 
uncertainty, visual disorder, motor dysfunction, communication deficit) and seven 
symptom items (headache, seizures, drowsiness, hair loss, itching, difficulty with 
bladder control and weakness of the legs) 17,18. 
 
Statistical methods 
The Chi-square test was used to compare categorical variables and the Wilcoxon 
test was applied to compare continuous variables. Events in survival models were 
defined as radiographic tumor progression for PFS2 and as death of any cause for 
PRS. The log-rank and bootstrap tests were used to compare median times and 
rates at fixed time points. Receiver operating characteristics (ROC) analysis was 
performed to establish MRI-based volume thresholds. Associations of surgery, EOR 
and ROC-derived tumor volume thresholds with outcome were analyzed in a Cox 
proportional hazards model. Age, KPS, MGMT promoter methylation, and steroid 
intake were included in this Cox model. Mann-Whitney-U-test was performed for QoL 
data analysis, as the data were largely not normally distributed. 
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Results 
 
Patient characteristics 
Of 105 patients enrolled, 71 patients underwent surgery prior to study entry (Figure 
1). Characteristics of patients who underwent surgery for recurrent disease versus 
patients who did not undergo surgery are summarized in Table 1. MGMT promoter 
methylation, first-line treatment, progression-free survival from first diagnosis 
following first-line treatment (PFS1) as well as KPS and steroid intake at study entry 
were balanced between both groups.  
Tumor volumes at recurrence were similar in patients who did or did not undergo 
surgery, but post-operative tumor volumes at study entry were smaller in the surgical 
cohort than in patients that did not undergo surgery. Radiographic CRET was 
achieved in 40 of 59 assessable patients (67.8%) who underwent surgery. Among 
patients who underwent surgery, MGMT promoter methylation, first-line treatment, 
PFS1, as well as KPS and steroid intake at study entry were balanced between 
patients with CRET versus incomplete resection. Preoperative tumor volumes at 
recurrence were larger in patients with incomplete resection (p=0.004), tumors with 
incomplete resection were more often localized in eloquent regions (p=0.178), (Table 
S1). One patient developed a post-operative wound infection within the first month 
after surgery and required discontinuation of TMZ, but no other severe complications 
from tumor resection were documented. 
 
Outcome by surgery 
Clinical outcome parameters were comparable in patients who underwent surgery 
versus patients who did not undergo surgery for recurrent disease prior to study entry 
(Figure 2A,B, Table S2). PRS was 11.4 months (95% CI, 8.4-12.3) in patients who 
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underwent surgery versus 9.8 months (95% CI, 6.6-15.1) in patients who did not 
undergo surgery (p=0.633).  
Next we explored a prognostic role for EOR. Among patients who underwent surgery 
at recurrence, PRS was longer in patients with CRET (12.9 months [95% CI, 11.5-
18.2]) than in patients with incomplete tumor resection (6.5 months [95% CI, 3.6-9.9]) 
(p<0.001) (Figure 2C,D, Table 2). Incomplete tumor resection was even associated 
with a trend to inferior PRS compared to patients who did not undergo surgery (6.5 
versus 9.8 months, p=0.052) (Figure 2E,F, Table S3). Comparing outcome between 
no surgery and CRET in the univariate analysis, there was an advantage for CRET 
as far as PFS2 is concerned: 1.87 (CI95%: 1.84-1.9) months vs. 3.5 (CI95%: 1.8-5.2) 
months, log-rank p = 0.05. The difference was pronounced, however, not statistically 
significant for PRS: 9.6 (CI95% 6.2-12.9) months vs. 13.2 (CI95% 9.1-17.3) months, 
log-rank p = 0.087. Multivariate analysis revealed CRET to be prognostic for PRS (p 
=0.05) besides MGMT and KPS (please also see Table S7). Volumetric analysis 
across the entire study population of volumes prior to study entry revealed (CE-) T1 
volumes with as well as (CE-) T1 without necrosis to be highly associated (p 
<0.0001) with longer PFS2 and PRS. 
Of note, tumor volumes at study entry were similar in patients who underwent 
incomplete tumor resection (median 4.0 cm3 [range: 1.1-25.3]) versus patients who 
did not undergo surgery (median 5.1 cm3 [range: 1.0-25.2]) (p=0.635). Tumor 
location regarding eloquent brain regions was not significant for outcome (11.08 
months [95% CI, 9.3-12.9] vs. 11.5 months [95% CI, 5.2-17.8]). 
Finally, we analyzed the outcome of all patients with contrast-enhancing tumor at 
study entry (e.g. patients without surgery and those with an incomplete resection) 
versus patients with CRET (Figure2G,H, Table S4). Detection of contrast-enhancing 
tumor was associated with shorter PFS2 (p=0.025) and PRS (p=0.007). ROC 
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analysis using the median PRS (10.5 months) for determining the volume threshold 
for discrimination between inferior and superior post-recurrence survival was 
performed: concerning the postoperative (CE-) T1 with and without necrosis as well 
as T2/FLAIR volumes, a threshold could not be determined due to the large number 
of cases with complete resection.  
 
Multivariate modeling of post-operative outcome  
We applied a Cox proportional hazards model to identify prognostic factors after 
surgery. Univariate analyses of the association of factors that were included in this 
Cox model with outcome are summarized in Table S5. CRET was prognostic for PRS 
on multivariate analysis, in contrast to age, MGMT promoter methylation status, KPS 
or steroid intake, at study entry (Table 3). Gender or study arm were also not 
prognostic when tested in this model as additional single variables (data not shown). 
CRET was not prognostic for PRS when Cox proportional hazards modeling was 
applied to PFS2 (p=0.061). When CRET was replaced surgery “yes vs no” in the 
same Cox model, only MGMT promoter methylation status was prognostic for OS 
(Table S6) and PFS2 (p=0.003) in the log-rank test. 
 
Quality of life 
Regarding the entire group at the first follow up after 8 weeks, patients who received 
surgery had higher cognitive functioning values (p=0.046). Constipation was also 
more common in this group (p=0.039).  Patients who underwent an incomplete 
resection were more likely to suffer from general motor dysfunction (p=0.04) and to 
have a worse global health status (p=0.008) compared to those who underwent 
CRET. 
 
N-O-D-15-00669R1 
 
11 
Discussion 
 
In contrast to the existing standard of care in primary GBM, treatment of GBM 
progression after standard of care treatment remains poorly defined and is 
increasingly individualized, taking into considerations prior treatment, time of relapse, 
pattern of tumor spread at relapse as well as increasingly molecular marker profiles 
1,11,19. Surgery with complete resection of solid, contrast-enhancing tumor has been 
shown to be associated with improved survival in newly diagnosed GBM7,8,20-22. 
However, only a minority of patients is considered eligible for second surgery - KPS, 
tumor volume and eloquent tumor location have recently been identified as selection 
criteria for patients to benefit from reoperation23,24. Only 13-30% of all recurrent GBM 
patients are considered as candidates for a second surgery 25. 
Yet, the evidence for these recommendations is low and commonly based on 
retrospective case series. The DIRECTOR trial explored tolerability and efficacy of 
two different regiments of dose-intensified TMZ in patients with GBM at first 
progression13. Since this trial cohort is clinically well annotated and both TMZ 
treatment arms had identical outcomes, it provides an excellent opportunity to 
explore the association of surgery at recurrence with outcome. The majority (68%) of 
patients had surgery for recurrent disease prior to being enrolled in this trial. This 
number is considerably higher than in previous reports on re-operation in recurrent 
GBM (13-30%), however, the present data are based on a multicenter trial enrolling 
patients from 10 large neurosurgical centers25,26. As reported in the primary report of 
the DIRECTOR trial, patients with versus without surgical intervention prior to study 
enrolment had a similar outcome13. Recently, in a cohort study from a prospective 
registry in Italy with 764 patients over a period of 14 years no survival benefit was 
detected for reoperation, similar to an analysis done by the North American Brain 
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Tumor Consortium (NABTC) on 758 patients being enrolled over 11 years25-27. 
However, all three reports did not consider the volumetric EOR but merely whether 
patients had undergone second surgery at all. In addition, reports in which extent of 
re-resection was considered were neither controlled for additional therapies nor were 
data prospectively collected according to a protocol. 
Here we categorized the surgical intervention at recurrence in a simple binary mode: 
after reoperation 40 patients had no residual tumor determined by volumetry of 
contrast-enhanced MRI whereas 19 patients did. A comparison of these two cohorts 
demonstrated that extent of resection was prognostic for outcome. Further sensitivity 
analyses demonstrated that the presence versus absence of residual tumor at study 
entry remained prognostic irrespective of surgery. In fact, incomplete resection 
showed even a trend to inferior outcome compared to no resection at all prior to 
study entry. Of note, it has to be assumed that some patients undergoing second 
surgery in this setting had postoperative morbidity that prevented them from being 
eligible for the DIRECTOR trial according to the inclusion criteria. Hence, the cohort 
of this study has undergone selection by omitting patients with severe postoperative 
complications and the present analysis can focus more specifically on the role of 
resection itself. In addition, the uniform treatment of all patients with dose-intensified 
TMZ re-challenge provides a much more homogeneous cohort to analyze the role of 
extent of resection since the spectrum of additional therapy after re-resection was 
heterogeneous in previous studies.  
A recent literature review performed by use of the PubMed and Ovid Medline 
databases for 1980 through 2013 revealed only 31 studies with data from single or 
multiple institutions. Twenty-nine proposed a survival benefit or improved functional 
status after reoperation for recurrent high-grade glioma10. This was confirmed in a 
recent study analyzing 503 patients28. However, selection criteria for and influence of 
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additional post re-resection therapy remained unclear. Even more, the role of 
incomplete re-resection is yet vague since no comparison with matched cohorts of 
non-re-resected patients had been performed. More aggressive resection bears the 
risk of increased surgical morbidity and has been found to be doubled once 
volumetric resection of more than 80% was achieved12. The influence of procedure-
related morbidity on timing and intensity of additional antitumor treatment after re-
resection had never been analyzed although one might assume that patients with 
surgical complications might be withheld from intensified oncological therapy in the 
context of recurrent GBM. These confounding factors do not interfere in our study 
because of inclusion criteria and treatment design of the DIRECTOR trial which led to 
a very homogeneous cohort. 
Here we report that only those patients experience prolonged survival in whom a 
complete resection of the solid contrast-enhancing tumor mass was accomplished. 
Quality of life regarding cognitive and neurological function was superior in this 
cohort compared to patients with measurable disease on MRI after reoperation. 
Compared to the non-resected cohort, incomplete resection did not result in better 
outcome, neither regarding survival nor quality of life. Indeed, PRS was shorter by 
trend in patients with residual tumor after reoperation despite similar tumor volumes. 
These considerations allow to conclude that surgery for recurrent GBM should only 
be considered if CRET can be safely achieved.  
Future studies dealing with post-recurrence treatment have to analyze whether the 
study arms are balanced for CRET. Clark et al concluded from their NABTC analysis 
that data from patients with and without reoperation might be combined for the 
assessment of new treatment options since PFS-6 and OS were similar in both 
cohorts. However, the simple discrimination solely between surgery yes/no revealed 
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no difference in the past in contrast to our study and former reports adjusting for 
extent of re-resection12,13,25,26,29.  
Our study has inherent limitations. Although the data were collected prospectively, it 
is still a retrospective, exploratory analysis that was not pre-specified. Furthermore, it 
still remains a possibility that patients with tumors that were amenable to CRET were 
per se tumors with a better prognosis due to a different biology, e.g. being less 
invasive. A randomized trial to prospectively assess the role of complete resection at 
GBM progression has recently started (NCT 02394626). 
 
Conclusion 
According to the data of this well controlled study population surgery at first 
recurrence of GBM improves outcome both in terms of survival and quality of life only 
if complete resection of CE-enhancing tumor is safely achieved.  
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Figure legends 
 
Figure 1. Consort Chart. Surgery and extent of resection prior to study entry in the 
DIRECTOR trial. Arm A [one week on (120 mg/m(2) per day)/one week off 
temozolomide];  Arm B [3 weeks on (80 mg/m(2) per day)/one week off 
temozolomide]. Black: patients who did not undergo surgery; White: patients with 
CRET (complete resection of contrast-enhancing tumor); light grey: patients with 
incomplete resection 
 
   
Figure 2. Outcome by surgery and residual disease on the baseline MRI. PFS2 
(time to next progression) (A) and PRS (B) in all patients who underwent surgery for 
recurrent disease (N=71) versus patients who did not undergo surgery (N=34). PFS2 
(C) and PRS (D) in patients who underwent surgery for recurrent disease prior to 
study entry with residual disease (N=19) versus CRET (N=40) on the baseline MRI. 
PFS2 (E) and PRS (F) in patients with incomplete tumor resection (N=19) versus 
patients who did not undergo surgery (N=34). PFS2 (G) and PRS (H) in patients with 
radiographically detectable disease on the baseline MRI (N=53) versus patients with 
CRET (N=40).  
 
Table 1. Patient characteristics prior to enrolment. 
 Surgery for recurrence  
 Yes 
N=71 
No 
N=34 
p 
Age at diagnosis    
  Median (years) 55 59.5 
0.495 
  Range (years) 25-77 21-72 
Gender: N (%)    
  Male 48 (67.6) 21 (61.8) 
0.555 
  Female 23 (32.4) 13 (38.2) 
MGMT promoter: N (%)    
  Methylated 31 (43.7) 15 (44.1) 
 0.965 
  Unmethylated 40 (56.3) 19 (55.9) 
First-line therapy:  
Number of maintenance TMZ cycles 
   
  Median 6.0 6.0 
0.444 
  Range 2-12 2-12 
Time to first progression (months)    
  Median 11.5 10.7 0.366 
  Range 3.9-80.9 5.4-50.0 
Tumor volume at recurrence (cm3)      
 Median 9.5 5.1 
0.234 
 Range 0.2-71.4 1.0-23.2 
Tumor volume at study entry (cm3)     
 Median 0.3 5.1 
<0.001 
 Range 0-25.0 1.0-23.2 
KPS at study entry: N (%)    
  90-100 40 (56.3) 20 (58.8) 
0.880   70-80 22 (31.0) 9 (26.5) 
  <70 9 (12.7) 5 (14.7) 
Steroids at study entry: N (%)    
  Yes 20 (31.3) 8 (28.6) 
0.797 
  No 44 (68.7) 20 (71.4) 
Study arm: N (%)    
  Arm A 34 (47.9) 18 (52.9) 
0.628 
  Arm B 37 (52.1) 16 (47.1) 
*Considers only patients with available imaging data; MGMT: O6-methylguanine-DNA-methyltransferase 
thylguanine-DNA-methyltransferase TMZ: temozolomide; KPS: Karnofsky Performance Score 
 
Table 2. Outcome by extent of resection. 
 
 Extent of resection  
 GTR Incomplete  
        
 Patients Events Time in 
months 
(95% CI) 
Patients Events Time in 
months 
(95% CI) 
p 
Median PFS2 40 37 3.5 [2.0-5.1] 19 19 1.9 [1.3-3.5] 0.016 
Median PRS 40 34 12.9 
[11.5-18.2] 
19 18 6.5 [3.6-9.9] <0.001 
        
   Rate in % 
(95% CI) 
  Rate in% 
(95% CI) 
 
PFS2 at 6 months 39 29 25.6 18 16 11.1 0.063 
[11.3-40.0] [5.0-27.2] 
Survival rate at 12 
months from first 
study drug 
administration 
39 16 59.0 
[42.8-75.1] 
18 15 16.7 
[2.4-35.7] 
<0.001 
GTR: gross total resection; PFS2: time to next progression; PRS: post-recurrence survival; CI: confidence interval 
Table S1. Patient characteristics by extent of resection. 
 
 Extent of resection  
 GTR 
N=40 
Incomplete 
N=19 
p 
Age at diagnosis    
  Median (years) 56.5 55 
0.773 
  Range (years) 25-77 39-76 
Gender: N (%)    
  Male 25 (62.5) 16 (84.2) 
0.091 
  Female 15 (37.5) 3 (15.8) 
MGMT promoter: N (%)    
  Methylated 20 (50.0) 7 (36.8) 
0.343 
  Unmethylated 20 (50.0) 12 (63.2) 
First-line therapy:  
Number of maintenance TMZ cycles 
   
  Median 6.0 6.0 
0.875 
  Range 2-12 2-12 
Time to first progression (months)    
  Median 12.0 10.6 
0.897 
  Range 3.9-80.9 7.0-51.9 
Tumor volume at recurrence (cm3)    
 Median 6.9 21.5 
0.004 
 Range 0.2-58.2 1.2-71.4 
Tumor volume at study entry (cm3)    
 Median 0 4.0 
N.A. 
 Range N.A. 1.1-25.3 
KPS at study entry: N (%)    
  90-100 26 (65.0) 8 (42.1) 
0.235   70-80 11 (27.5) 8 (42.1) 
  <70 3 (7.5) 3 (15.8) 
Steroids at study entry: N (%)    
  Yes 15 (40.5) 3 (18.8) 
0.206 
  No 22 (59.5) 13 (81.2) 
Study arm: N (%)    
  Arm A 22 (55.0) 9 (47.4) 
0.583 
  Arm B 18 (45.0) 10 (52.6) 
Eloquent location    
  Yes 28 16 
0.187 
  No 12 3 
 
 
 
 
 
Table S2. Outcome by surgery for recurrence. 
 
 Surgery for recurrence  
 Yes No  
        
 Patients Events Time in 
months 
(95% CI) 
Patients Events Time in 
months 
(95% CI) 
p 
Median PFS2 71 68 2.0 [1.9-3.7] 34 31 1.9 [1.8-2.0] 0.360 
Median PRS  71 64 11.4  
[8.4-12.3] 
34 31 9.8  
[6.6-15.1] 
0.633 
        
   Rate in % 
(95% CI) 
  Rate in% 
(95% CI) 
 
PFS2 at 6 months 69 54 21.7 
[11.8-31.8] 
33 27 18.2 
[4.3-32.1] 
0.230 
Survival rate at 69 40 42.0 33 19 42.4 0.885 
12 months from 
first study drug 
administration 
[30.1-54.0] [24.6-60.2] 
 
Table S3. Outcome by surgery for recurrence in patients with radiographically detectable disease. 
 
 Surgery for recurrence  
 Yes No  
        
 Patients Events Time in 
months 
(95% CI) 
Patients Events Time in 
months 
(95% CI) 
p 
Median PFS2 19 19 1.9 [1.3-3.4] 34 31 1.9 [1.8-2.0] 0.405 
Median PRS from 
first study drug 
administration 
19 18 6.5 [3.6-9.9] 34 31 9.8 [6.6-15.1] 0.052 
        
   Rate in% 
(95% CI) 
  Rate in% 
(95% CI) 
 
PFS2 at 6 months 18 16 11.1 33 27 18.2 0.760 
[5.0-27.2] [4.3-32.1] 
Survival rate at 12 
months from first 
study drug 
administration 
18 15 16.7 
[2.4-35.7] 
33 19 42.4 
[24.6-60.2] 
0.063 
 
Table S4. Outcome by radiographically detectable disease on the baseline MRI at study entry. 
 
 Radiographically detectable disease  
 Yes No  
 Patients Events Time in months 
(95% CI) 
Patients Events Time in months 
(95% CI) 
p 
Median PFS2 53 50 1.9 [1.8-1-9] 40 37 3.5 [2.0-4.4] 0.025  
Median PRS from first 
study drug 
administration 
53 49 9.2 [6.5-11.4] 40 34 12.9 
[11.7-18.7] 
0.007 
        
   Rate in% 
(95% CI) 
  Rate in % 
(95% CI) 
 
PFS2 at 6 months 51 43 15.7 
[5.4-26.0] 
39 29 25.6 
[11.3-40.0] 
0.035 
Survival rate at 12 
months from first study 
drug administration 
51 34 33.3 
[19.9-46.7] 
39 16 59.0 
[42.8-75.1] 
0.005 
 
Table S5. Univariate analyses of associations with inferior survival. 
 
 Hazard ratio and 
95% CI 
p 
Extent of resection: GTR versus incomplete 0.35 (0.19-0.64) 0.001 
Age at study entry: 18-54 versus 55+ years 1.10 (0.73-1.66) 0.647 
MGMT promoter: methylated versus unmethylated 0.45 (0.29-0.68) <0.001 
KPS at study entry: 90-100% versus KPS 50-80% 0.71 (0.47-1.01) 0.099 
Steroids at study entry: no versus yes 1.21 (0.76-1.94) 0.427 
 
Table S6. Multivariate analyses of predictors of inferior survival.a 
 
 Hazard ratio and 
95% CI 
p 
Surgery at recurrence 0.73 (0.45-1.20) 0.213 
Age at study entry: 18-54 versus 55+ years 1.04 (0.65-1.66) 0.870 
MGMT promoter: methylated versus unmethylated 0.38 (0.23-0.63) <0.001 
KPS at study entry: 90-100% versus KPS 50-80% 0.64 (0.40-1.03) 0.067 
Steroids at study entry: no versus yes 0.85 (0.51-1.40) 0.512 
 
a Patients with complete clinical and imaging data (N=91). 
 
Table S7. Multivariate analyses of predictors of inferior outcome regarding GTR/no 
surgerya. 
 
PRS Hazard ratio and 
95% CI 
p 
GTR versus no surgery 0.57 (0.32-0.99) 0.05 
Age at study entry: 18-54 versus 55+ years 0.87 (0.49-1.54) 0.63 
MGMT promoter: methylated versus unmethylated 0.30 (0.16-0.55) <0.0001 
KPS at study entry: 90-100% versus KPS 50-80% 0.5 (0.28-0.90) 0.02 
Steroids at study entry: no versus yes 0.82 (0.37-1.20) 0.18 
PFS2 Hazard ratio and 
95% CI  
p 
GTR versus no surgery 0.69 (0.39-1.20) 0.18 
Age at study entry: 18-54 versus 55+ years 0.66 (0.35-1.24) 0.20 
MGMT promoter: methylated versus unmethylated 0.55 (0.31-0.97) 0.04 
KPS at study entry: 90-100% versus KPS 50-80% 0.90 (0.49-1.66) 0.73 
Steroids at study entry: no versus yes 0.57 (0.32-1.01) 0.05 
 
aPatients with complete clinical and imaging data. GTR: gross total resection; MGMT: O6-methylguanine-
DNA-methyltransferase thylguanine-DNA-methyltransferase; KPS: Karnofsky Performance Score
 
 
 

